Pharmalot

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny

Pharmalot Ed Silverman

STAT Plus: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback

Pharmalot Ed Silverman

STAT Plus: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro

Pharmalot Ed Silverman

STAT Plus: How a cash-prize system that phases out patents may lower drug prices

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses

Pharmalot Ed Silverman

STAT Plus: After a high-profile pressure campaign, Cepheid agrees to sell a TB test at cost

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing

Pharmalot Ed Silverman

STAT Plus: South Africa investigates Johnson & Johnson over ‘excessive pricing’ for its TB drug

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: House panel inches into fixing drug shortages; pharma could face legal action over improper patent listings

Pharmalot Ed Silverman

STAT Plus: FTC warns drugmakers they can face legal action over improper patent listings

Pharmalot Ed Silverman

STAT Plus: Medicare is urged to monitor how rebates affect Part D drug spending, but agency demurs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: White House imposes price limits for Regeneron Covid drug; lawmakers push federal agencies to prevent patent abuses

Pharmalot Lizzy Lawrence and Ed Silverman

STAT Plus: Novelist John Green launches attack on Cepheid over the price of its TB test

Pharmalot Ed Silverman

STAT Plus: Lawmakers introduce bill to require drugmakers to provide key info to both FDA and U.S. Patent Office

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA panel says popular decongestant doesn’t work; U.S. warns companies over illegally marketed eye products

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Is Pascal Soriot leaving AstraZeneca? PBMs try to counter congressional crackdown

Pharmalot Jason Mast

STAT Plus: Pharmalittle: Biden’s NIH nominee will get a hearing; top Democrat backs bill to ban PBM spread pricing

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Adam Feuerstein

STAT Plus: Pharmalittle: Novartis R&D hub’s name change reflects strategy shift; Lilly’s Mounjaro backed by U.K. watchdog

Pharmalot Jason Mast

STAT Plus: Pharmalittle: South Africa ‘bullied’ into one-sided Covid vaccine deals; Astellas drops Medicare price-negotiation suit

Pharmalot Ed Silverman

STAT Plus: South Africa was forced into ‘one-sided’ deals with Covid-19 vaccine suppliers, contracts reveal

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Novartis is losing its chief commercial officer; vaccine experts urge more inclusivity in clinical trials

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Novartis is latest drugmaker to sue over Medicare negotiations; Illumina names a new CEO

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: FTC settles with Amgen over $28 billion deal for Horizon

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: How 98 days may cost J&J big bucks; Walgreens CEO departs

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.S. pharma layoffs continue to climb; senators push insulin makers for details of low-cost programs